Danaher (NYSE:DHR) Updates FY 2025 Earnings Guidance

Danaher (NYSE:DHR - Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 7.700-7.800 for the period, compared to the consensus estimate of 7.702. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Leerink Partners raised their price target on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Wolfe Research lowered their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. HSBC reduced their price target on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Argus reduced their price target on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Finally, Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Trading Up 2.3%

DHR stock traded up $4.54 during mid-day trading on Thursday, reaching $202.43. The company's stock had a trading volume of 5,703,952 shares, compared to its average volume of 4,250,817. Danaher has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The business's 50 day moving average price is $195.94 and its 200 day moving average price is $204.39. The company has a market cap of $144.88 billion, a price-to-earnings ratio of 43.10, a price-to-earnings-growth ratio of 2.65 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.80% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. The company's revenue was up 3.4% compared to the same quarter last year. On average, equities research analysts predict that Danaher will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.